Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS)
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Insulin resistance (IR) plays a pivotal role in PCOS. Insulin-sensitizer agents such as metformin and inositols have been shown to improve the endocrine and metabolic aspects of PCOS. The purpose of this study is to compare their effects on the clinical and metabolic features of the women with PCOS. Fifty PCOS women with IR and/or hyperinsulinemia were randomized to treatment with metformin (1500 mg/day) or myo-inositol (4 g/day). IR was defined as HOMA-IR >2.5, while hyperinsulinemia was defined as a value of AUC for insulin after a glucose load over the cutoff of our laboratory obtained in normal women. The Matsusa Index has been calculated. The women have been evaluated for insulin secretion, BMI, menstrual cycle length, acne and hirsutism, at baseline and after 6 months of therapy. The results obtained in both groups were similar. The insulin sensitivity improved in both treatment groups. The BMI significantly decreased and the menstrual cycle was normalized in about 50% of the women. No significant changes in acne and hirsutism were observed. The two insulin-sensitizers, metformin and myo-inositol, show to be useful in PCOS women in lowering BMI and ameliorating insulin sensitivity, and improving menstrual cycle without significant differences between the two treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting 6–10% of reproductive-aged women, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology according to the Rotterdam criteria1–3.”
In the citing paper
“Twenty studies compared MI alone at doses of 1 to 4 g daily either alone or in combination with FA 200 to 400 mcg daily (25-27, 30-34, 41, 42, 44, 46-55) against the comparators of metformin, FA alone, or placebo.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [33]
In the citing paper
“Twelve used metformin at doses of 1000 mg to 2000 mg daily alone or in combination with FA as a comparator (26, 28, 30, 33, 39, 41, 42, 49-54, 56).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [33]
In the citing paper
“In a meta-analysis of 6 trials, GI AEs were less common in the MI group compared with metformin (OR 0.09, 0.02 to 0.37, I2 = 69%, 6 trials, Fig. 5Q) (26, 33, 51-54).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [33]
In the citing paper
“Reproductive outcomes including resumption of normal menstrual cycles (Fig. 5N, 3 studies) (26, 33, 51) or rate of ovulation (Fig. 5O, 2 studies)(49, 50) did not differ between groups.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [33]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
2 retracted
- Retracted
RETRACTED: Contribution of myo-inositol to reproduction
Papaleo, E., Unfer, V., Baillargeon, J., & Chiu, T. T. Y. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.09.008 · Cited by 88
RetractedMatthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“5 were considered insulin resistant [26].”
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Phosphoinositides in cell regulation and membrane dynamics
Di Paolo, G., & De Camilli, P. (2006) · Nature · doi:10.1038/nature05185 · Cited by 2,790 · cited 3×
“The concentrations of LH, FSH, estradiol, prolactin, A, T, DHEAS, 17OHP F, glucose and insulin were determined as previously reported [28].”
BackgroundInfluentialThe Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 2×
“The polycystic ovary syndrome (PCOS) affects about 6–10% of women in the reproductive age, characterized by chronic anovulation, hirsutism and acne, sterility and polycystic ovarian ultrasound morphology (PCOM) [1,2].”
BackgroundInsulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458 · cited 1×
“Most of the patients with PCOS are affected by insulin resistance [2,4], dyslipidemia [5], a low grade of chronic inflammation, vascular and endothelial dysfunctions[6,7].”
BackgroundObesity and the polycystic ovary syndrome
Gambineri, A., Pelusi, C., Vicennati, V, Pagotto, U., & Pasquali, R. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801994 · Cited by 836
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786
Cited by
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites
Chen, W., & Pang, Y. (2021) · Metabolites · doi:10.3390/metabo11120869 · Cited by 228
Feng, J., Wang, X., Ye, X., Ares, I., Lopez-Torres, B., Martínez, M., Martínez-Larrañaga, M.-R., Wang, X., Anadón, A., & Martínez, M.-A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106114 · Cited by 194
Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017) · Endocrine Connections · doi:10.1530/ec-17-0243 · Cited by 188
“Studies were excluded for several reasons including (a) data of the outcome were unavailable or not expressed in the numerical form (39), (b) patients were treated with MI combined with other molecules such as multivitamin complex (40), lactoferrin and bromelin (41) or oral contraceptives pills…”
Nutrition Strategy and Life Style in Polycystic Ovary Syndrome—Narrative Review
Szczuko, M., Kikut, J., Szczuko, U., Szydłowska, I., Nawrocka-Rutkowska, J., Ziętek, M., Verbanac, D., & Saso, L. (2021) · Nutrients · doi:10.3390/nu13072452 · Cited by 165
“However, the administration of metformin is associated with side effects that are not experienced with inositol [92].”
Background
Metadata
- Authors
- Fruzzetti, F., Perini, D., Russo, M., Bucci, F., & Gadducci, A.
- Affiliations
- University of Pisa (IT)
- Corresponding author
- Fruzzetti, Franca
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2016-11-03
- Volume
- 33
- Issue
- 1
- Pages
- 39-42
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2548095383
- Cited by
- 135
- References
- 31
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 23 · 2023: 21 · 2022: 16 · 2021: 22 · 2020: 13 · 2019: 11 · 2018: 3 · 2017: 7
- FWCI
- 9.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gynecological Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, metformin, myo-inositol, insulin resistance, insulin sensitizers, hyperinsulinemia, body mass index, menstrual cycle, acne, hirsutism, insulin secretion
- MeSH terms
- Adolescent, Adult, Female, Humans, Hypoglycemic Agents, Inositol, Insulin Resistance, Metformin, Polycystic Ovary Syndrome, Vitamin B Complex, Outcome Assessment, Health Care, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). https://app.cochat.ai/papers/10.1080/09513590.2016.1236078
- The paper
- Fruzzetti, F., Perini, D., Russo, M., Bucci, F., & Gadducci, A. (2017). Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecological Endocrinology. https://doi.org/10.1080/09513590.2016.1236078
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.